Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review
Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women...
Saved in:
| Published in | Journal of ovarian research Vol. 11; no. 1; pp. 52 - 7 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
22.06.2018
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1757-2215 1757-2215 |
| DOI | 10.1186/s13048-018-0426-8 |
Cover
| Abstract | Background
Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed.
Case presentation
We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review.
Conclusions
A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. |
|---|---|
| AbstractList | Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed. Case presentation We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review. Conclusions A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. Keywords: Alpha-fetoprotein, Ovarian clear cell adenocarcinoma, Fetal gut differentiation Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed. A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed.BACKGROUNDAlpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed.We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review.CASE PRESENTATIONWe report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review.A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear.CONCLUSIONSA total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed. We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review. A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. BackgroundAlpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed.Case presentationWe report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review.ConclusionsA total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed. Case presentation We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review. Conclusions A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. Abstract Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further follow-up. Epithelial ovarian carcinoma (EOC) rarely secretes AFP, especially for clear cell type and in the postmenopausal women. Based on the limited knowledge about AFP-producing clear cell type EOC, a case and literature review on this topic is extensively reviewed. Case presentation We report a 55-year-old postmenopausal woman experienced vaginal spotting for one month, and serum level of AFP was 60,721 ng/ml initially. Histological examination was clear cell type EOC. Tumor cells revealed strong immunoreactivity for glypican-3 (GPC3) and AFP and weak for hepatocyte nuclear factor-1 beta (HNF-1 beta), but negative for CD30, making the diagnosis of AFP-producing clear cell type EOC with fetal gut differentiation in focal areas, FIGO (International Federation of Gynecology and Obstetrics) IIIc. Although the patient underwent an intensive treatment, including optimal debulking surgery and multi-agent chemotherapy, the patient died of disease. To provide a better understanding of clinical and molecular characteristics of the AFP-producing clear cell type EOC, we conducted a systematic literature review. Conclusions A total of three papers described the AFP-producing clear cell type EOC are available. The overall survival rate of these cases, including the current case is 50%. Although immunohistochemical examination is not always needed in routine for the diagnosis of clear cell type EOC, to distinguish from other tumors, especially germ cell tumors, or to provide the better way to monitor therapeutic response or to evaluate the disease status, immunostaining, including GPC3, HNF-1 beta, CD30, cytokeratin 7 or 20, and AFP is taken into account. Due to rarity, the appropriate chemotherapy regimen and the biological behavior of AFP-producing clear cell type EOC are still unclear. |
| ArticleNumber | 52 |
| Audience | Academic |
| Author | Chao, Wei-Ting Chuang, Chi-Mu Wang, Peng-Hui Lai, Chiung-Ru Liu, Chia-Hao Chen, Yi-Jen |
| Author_xml | – sequence: 1 givenname: Wei-Ting surname: Chao fullname: Chao, Wei-Ting organization: Faculty of Medicine, College of Medicine, Fu-Jen Catholic University, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine – sequence: 2 givenname: Chia-Hao surname: Liu fullname: Liu, Chia-Hao organization: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine – sequence: 3 givenname: Chiung-Ru surname: Lai fullname: Lai, Chiung-Ru organization: Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Department of Pathology, Taipei Veterans General Hospital – sequence: 4 givenname: Yi-Jen surname: Chen fullname: Chen, Yi-Jen organization: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine – sequence: 5 givenname: Chi-Mu orcidid: 0000-0001-6697-712X surname: Chuang fullname: Chuang, Chi-Mu email: cmjuang@gmail.com organization: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Department of Midwifery and Women Health Care, National Taipei University of Nursing and Health Sciences – sequence: 6 givenname: Peng-Hui surname: Wang fullname: Wang, Peng-Hui email: phwang@vghtpe.gov.tw, phwang@ym.edu.tw, pongpongwang@gmail.com organization: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Department of Medical Research, China Medical University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29933751$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ul1rFDEUHaRiP_QH-CIBQXyZmkw-xwdhKX4UCr7oc7iTyeymzCZrktniH_B3m-m2dreohCHh5pxz556c0-rIB2-r6iXB54Qo8S4RipmqMSkfa0StnlQnRHJZNw3hR3vn4-o0pWuMRaMYfVYdN21LqeTkpPq1GDcrqAebwyaGbJ2vy95PxvklCluIDjwyo4WIjB1HBL31wUAs92EN6MblFSpkGNFyyqh3w2Cj9dlBdsG_R4AiRIsMJIui3YSYEfgejS7bCHmKc3Xr7M3z6ukAY7Iv7vaz6vunj98uvtRXXz9fXiyuaiMoy3XHLZOEc2KE4QB9D9Jw1bfCdB2hRChJB9UZ2TEOXMmG40Z1tAM6UMtN29Cz6nKn2we41pvo1hB_6gBO3xZCXGqI2ZWBNZGsVUx0irSUtYQrizmQXgncMkqtLFofdlqbqVvb3pSxI4wHooc33q30Mmy1wIQzQYrA2zuBGH5MNmW9dml2GbwNU9IN5opj2Yq51-tH0OswRV-sKihJlGSEsQfUEsoAzg-h9DWzqF6Uji1uGjW3Pf8Lqqzerp0pCRtcqR8Q3uwRVhbGvEphnOYnTofAV_uO_LHiPm4FIHcAE0NK0Q7auHwblfILbtQE6znYehdsXYKt52BrVZjkEfNe_H-cZsdJBeuXNj6Y9m_Sb-mCCUM |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_928234 crossref_primary_10_1007_s00418_021_02006_8 crossref_primary_10_1007_s00404_021_06017_7 crossref_primary_10_1097_JCMA_0000000000000252 crossref_primary_10_1097_PGP_0000000000000891 crossref_primary_10_1039_C8AN01978A crossref_primary_10_1111_his_15379 crossref_primary_10_3389_fmed_2021_799163 crossref_primary_10_3390_ijerph19031106 crossref_primary_10_1177_03000605221117218 crossref_primary_10_1039_C8AY01789A crossref_primary_10_1007_s00795_022_00336_7 crossref_primary_10_1515_jpem_2021_0382 |
| Cites_doi | 10.1097/00004347-198805000-00009 10.1046/j.1440-1827.1999.00840.x 10.1034/j.1600-0463.2002.100609.x 10.1186/1746-1596-7-9 10.1016/j.jcma.2017.06.018 10.1016/S0090-8258(03)00407-4 10.1007/s10147-008-0800-4 10.1016/j.tjog.2018.02.015 10.1097/00004347-199107000-00009 10.1097/01.PGP.0000055173.04957.66 10.1159/000325560 10.1111/j.1525-1438.2006.00564.x 10.1016/j.anndiagpath.2011.07.010 10.1034/j.1600-0412.2002.811115.x 10.1097/PGP.0000000000000213 10.1097/00004347-199907000-00015 10.1097/MD.0000000000003003 10.1016/j.gynor.2014.03.001 10.1111/j.1525-1438.2007.00952.x 10.1186/s13048-014-0091-5 10.1097/IGC.0000000000001149 10.1006/gyno.1998.5048 10.1097/PAS.0b013e31815a565a 10.1016/j.jcma.2016.04.001 10.1111/j.1447-0756.2011.01622.x 10.1006/gyno.1998.5119 10.1186/s13048-018-0393-0 10.1038/labinvest.2015.73 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s13048-018-0426-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1757-2215 |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_1749846b819349158e05a1d8609433e7 PMC6015461 A546902281 29933751 10_1186_s13048_018_0426_8 |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS EJD ESX FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO ICW IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ TR2 TUS UKHRP AAYXX ALIPV CITATION NPM PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c634t-b5e471551c6c5aadda7c58d96cbb1316873f8bc7b45a58725028b3ba3f3e5c923 |
| IEDL.DBID | BENPR |
| ISSN | 1757-2215 |
| IngestDate | Wed Aug 27 01:24:23 EDT 2025 Thu Aug 21 13:36:34 EDT 2025 Sun Aug 24 04:02:44 EDT 2025 Sat Jul 26 02:36:52 EDT 2025 Tue Jun 17 21:05:44 EDT 2025 Tue Jun 10 20:22:02 EDT 2025 Thu May 22 21:22:43 EDT 2025 Thu Apr 03 07:01:08 EDT 2025 Tue Jul 01 04:16:52 EDT 2025 Thu Apr 24 23:01:00 EDT 2025 Sat Sep 06 07:29:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Ovarian clear cell adenocarcinoma Fetal gut differentiation Alpha-fetoprotein |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c634t-b5e471551c6c5aadda7c58d96cbb1316873f8bc7b45a58725028b3ba3f3e5c923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0001-6697-712X |
| OpenAccessLink | https://www.proquest.com/docview/2071874144?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 29933751 |
| PQID | 2071874144 |
| PQPubID | 54971 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1749846b819349158e05a1d8609433e7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6015461 proquest_miscellaneous_2058507967 proquest_journals_2071874144 gale_infotracmisc_A546902281 gale_infotracacademiconefile_A546902281 gale_healthsolutions_A546902281 pubmed_primary_29933751 crossref_citationtrail_10_1186_s13048_018_0426_8 crossref_primary_10_1186_s13048_018_0426_8 springer_journals_10_1186_s13048_018_0426_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-22 |
| PublicationDateYYYYMMDD | 2018-06-22 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of ovarian research |
| PublicationTitleAbbrev | J Ovarian Res |
| PublicationTitleAlternate | J Ovarian Res |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | Y Maida (426_CR8) 1998; 71 E Tejerina Gonzalez (426_CR14) 2008; 52 Y Higuchi (426_CR23) 1984; 108 H Sahin (426_CR32) 2018; 11 N Kato (426_CR28) 2009; 31 CY Dai (426_CR6) 2018; 81 S Kamoi (426_CR19) 2002; 110 M Matsuta (426_CR15) 1991; 10 JM Hu (426_CR25) 2016; 79 I Konishi (426_CR7) 1988; 7 S Meguro (426_CR9) 2013; 17 A Abe (426_CR17) 2008; 18 R Bayrak (426_CR26) 2012; 7 E Suzuki (426_CR31) 2015; 95 CH Lee (426_CR13) 2002; 81 A Morimoto (426_CR3) 2014; 8 Y Takahashi (426_CR2) 2011; 37 C Faure Conter (426_CR4) 2018; 28 S Yigit (426_CR12) 2006; 16 PL Sung (426_CR33) 2018; 57 T Suzuki (426_CR22) 2003; 90 JSH Tsung (426_CR10) 2004; 25 T Arai (426_CR21) 1999; 18 S Ye (426_CR29) 2016; 95 H Senzaki (426_CR11) 1999; 49 A Cetin (426_CR1) 2007; 28 GE Esheba (426_CR27) 2008; 32 A Horiuchi (426_CR18) 1998; 70 LD Goyal (426_CR5) 2014; 7 K Nomura (426_CR20) 1992; 42 W Huang (426_CR30) 2016; 35 N Tochigi (426_CR16) 2003; 22 S Isonishi (426_CR24) 2009; 14 16803543 - Int J Gynecol Cancer. 2006 May-Jun;16(3):1439-41 12193212 - APMIS. 2002 Jun;110(6):508-14 12421179 - Acta Obstet Gynecol Scand. 2002 Nov;81(11):1080-2 19320191 - Anal Quant Cytol Histol. 2009 Feb;31(1):34-40 26945423 - Medicine (Baltimore). 2016 Mar;95(9):e3003 25366470 - J Ovarian Res. 2014 Nov 04;7:91 1378991 - Acta Pathol Jpn. 1992 May;42(5):372-5 17466041 - Int J Gynecol Cancer. 2008 Jan-Feb;18(1):168-72 12819394 - Int J Gynecol Pathol. 2003 Jul;22(3):266-71 24707459 - Gynecol Oncol Case Rep. 2014 Mar 12;8:24-6 12090598 - Int J Gynecol Pathol. 1999 Jul;18(3):277-80 22056036 - Ann Diagn Pathol. 2013 Feb;17(1):140-4 13678742 - Gynecol Oncol. 2003 Sep;90(3):662-6 26166716 - Int J Gynecol Pathol. 2016 Jan;35(1):66-71 29194189 - Int J Gynecol Cancer. 2018 Jan;28(1):77-84 6205636 - Arch Pathol Lab Med. 1984 Sep;108(9):710-2 1717389 - Int J Gynecol Pathol. 1991;10(3):302-10 2456275 - Int J Gynecol Pathol. 1988;7(2):182-9 15597858 - Eur J Gynaecol Oncol. 2004;25(6):745-8 29506569 - J Ovarian Res. 2018 Mar 5;11(1):21 18277882 - Am J Surg Pathol. 2008 Apr;32(4):600-7 27329402 - J Chin Med Assoc. 2016 Sep;79(9):477-88 26030369 - Lab Invest. 2015 Aug;95(8):962-72 9740709 - Gynecol Oncol. 1998 Aug;70(2):295-9 21827573 - J Obstet Gynaecol Res. 2011 Dec;37(12):1842-6 29217359 - J Chin Med Assoc. 2018 Feb;81(2):155-163 17624099 - Eur J Gynaecol Oncol. 2007;28(3):241-4 19225928 - Int J Clin Oncol. 2009 Feb;14(1):70-3 18702372 - Acta Cytol. 2008 Jul-Aug;52(4):490-4 22268990 - Diagn Pathol. 2012 Jan 23;7:9 29673670 - Taiwan J Obstet Gynecol. 2018 Apr;57(2):255-263 10355972 - Pathol Int. 1999 Feb;49(2):164-9 9784334 - Gynecol Oncol. 1998 Oct;71(1):133-6 |
| References_xml | – volume: 28 start-page: 241 issue: 3 year: 2007 ident: 426_CR1 publication-title: Eur J Gynaecol Oncol – volume: 7 start-page: 182 issue: 2 year: 1988 ident: 426_CR7 publication-title: Int J Gynecol Pathol doi: 10.1097/00004347-198805000-00009 – volume: 49 start-page: 164 issue: 2 year: 1999 ident: 426_CR11 publication-title: Pathol Int doi: 10.1046/j.1440-1827.1999.00840.x – volume: 110 start-page: 508 issue: 6 year: 2002 ident: 426_CR19 publication-title: APMIS doi: 10.1034/j.1600-0463.2002.100609.x – volume: 7 start-page: 9 year: 2012 ident: 426_CR26 publication-title: Diagn Pathol doi: 10.1186/1746-1596-7-9 – volume: 81 start-page: 155 issue: 2 year: 2018 ident: 426_CR6 publication-title: J Chin Med Assoc doi: 10.1016/j.jcma.2017.06.018 – volume: 90 start-page: 662 issue: 3 year: 2003 ident: 426_CR22 publication-title: Gynecol Oncol doi: 10.1016/S0090-8258(03)00407-4 – volume: 14 start-page: 70 issue: 1 year: 2009 ident: 426_CR24 publication-title: Int J Clin Oncol doi: 10.1007/s10147-008-0800-4 – volume: 57 start-page: 255 issue: 2 year: 2018 ident: 426_CR33 publication-title: Taiwan J Obstet Gynecol doi: 10.1016/j.tjog.2018.02.015 – volume: 10 start-page: 302 issue: 3 year: 1991 ident: 426_CR15 publication-title: Int J Gynecol Pathol doi: 10.1097/00004347-199107000-00009 – volume: 25 start-page: 745 issue: 6 year: 2004 ident: 426_CR10 publication-title: Eur J Gynaecol Oncol – volume: 22 start-page: 266 issue: 3 year: 2003 ident: 426_CR16 publication-title: Int J Gynecol Pathol doi: 10.1097/01.PGP.0000055173.04957.66 – volume: 52 start-page: 490 issue: 4 year: 2008 ident: 426_CR14 publication-title: Acta Cytol doi: 10.1159/000325560 – volume: 16 start-page: 1439 issue: 3 year: 2006 ident: 426_CR12 publication-title: Int J Gynecol Cancer doi: 10.1111/j.1525-1438.2006.00564.x – volume: 17 start-page: 140 issue: 1 year: 2013 ident: 426_CR9 publication-title: Ann Diagn Pathol doi: 10.1016/j.anndiagpath.2011.07.010 – volume: 81 start-page: 1080 issue: 11 year: 2002 ident: 426_CR13 publication-title: Acta Obstet Gynecol Scand doi: 10.1034/j.1600-0412.2002.811115.x – volume: 35 start-page: 66 issue: 1 year: 2016 ident: 426_CR30 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000213 – volume: 18 start-page: 277 issue: 3 year: 1999 ident: 426_CR21 publication-title: Int J Gynecol Pathol doi: 10.1097/00004347-199907000-00015 – volume: 95 issue: 9 year: 2016 ident: 426_CR29 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000003003 – volume: 8 start-page: 24 year: 2014 ident: 426_CR3 publication-title: Gynecol Oncol Case Rep doi: 10.1016/j.gynor.2014.03.001 – volume: 18 start-page: 168 issue: 1 year: 2008 ident: 426_CR17 publication-title: Int J Gynecol Cancer doi: 10.1111/j.1525-1438.2007.00952.x – volume: 7 start-page: 91 year: 2014 ident: 426_CR5 publication-title: J Ovarian Res doi: 10.1186/s13048-014-0091-5 – volume: 31 start-page: 34 issue: 1 year: 2009 ident: 426_CR28 publication-title: Anal Quant Cytol Histol – volume: 28 start-page: 77 issue: 1 year: 2018 ident: 426_CR4 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000001149 – volume: 70 start-page: 295 issue: 2 year: 1998 ident: 426_CR18 publication-title: Gynecol Oncol doi: 10.1006/gyno.1998.5048 – volume: 32 start-page: 600 issue: 4 year: 2008 ident: 426_CR27 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e31815a565a – volume: 79 start-page: 477 issue: 9 year: 2016 ident: 426_CR25 publication-title: J Chin Med Assoc. doi: 10.1016/j.jcma.2016.04.001 – volume: 42 start-page: 372 issue: 5 year: 1992 ident: 426_CR20 publication-title: Acta Pathol Jpn – volume: 37 start-page: 1842 issue: 12 year: 2011 ident: 426_CR2 publication-title: J Obstet Gynaecol Res doi: 10.1111/j.1447-0756.2011.01622.x – volume: 71 start-page: 133 issue: 1 year: 1998 ident: 426_CR8 publication-title: Gynecol Oncol doi: 10.1006/gyno.1998.5119 – volume: 11 start-page: 21 issue: 1 year: 2018 ident: 426_CR32 publication-title: J Ovarian Res. doi: 10.1186/s13048-018-0393-0 – volume: 95 start-page: 962 issue: 8 year: 2015 ident: 426_CR31 publication-title: Lab Investig doi: 10.1038/labinvest.2015.73 – volume: 108 start-page: 710 issue: 9 year: 1984 ident: 426_CR23 publication-title: Arch Pathol Lab Med – reference: 1717389 - Int J Gynecol Pathol. 1991;10(3):302-10 – reference: 10355972 - Pathol Int. 1999 Feb;49(2):164-9 – reference: 29194189 - Int J Gynecol Cancer. 2018 Jan;28(1):77-84 – reference: 13678742 - Gynecol Oncol. 2003 Sep;90(3):662-6 – reference: 6205636 - Arch Pathol Lab Med. 1984 Sep;108(9):710-2 – reference: 12090598 - Int J Gynecol Pathol. 1999 Jul;18(3):277-80 – reference: 12193212 - APMIS. 2002 Jun;110(6):508-14 – reference: 18277882 - Am J Surg Pathol. 2008 Apr;32(4):600-7 – reference: 19225928 - Int J Clin Oncol. 2009 Feb;14(1):70-3 – reference: 16803543 - Int J Gynecol Cancer. 2006 May-Jun;16(3):1439-41 – reference: 2456275 - Int J Gynecol Pathol. 1988;7(2):182-9 – reference: 17466041 - Int J Gynecol Cancer. 2008 Jan-Feb;18(1):168-72 – reference: 19320191 - Anal Quant Cytol Histol. 2009 Feb;31(1):34-40 – reference: 22056036 - Ann Diagn Pathol. 2013 Feb;17(1):140-4 – reference: 29506569 - J Ovarian Res. 2018 Mar 5;11(1):21 – reference: 27329402 - J Chin Med Assoc. 2016 Sep;79(9):477-88 – reference: 26166716 - Int J Gynecol Pathol. 2016 Jan;35(1):66-71 – reference: 9740709 - Gynecol Oncol. 1998 Aug;70(2):295-9 – reference: 26945423 - Medicine (Baltimore). 2016 Mar;95(9):e3003 – reference: 12421179 - Acta Obstet Gynecol Scand. 2002 Nov;81(11):1080-2 – reference: 18702372 - Acta Cytol. 2008 Jul-Aug;52(4):490-4 – reference: 29673670 - Taiwan J Obstet Gynecol. 2018 Apr;57(2):255-263 – reference: 21827573 - J Obstet Gynaecol Res. 2011 Dec;37(12):1842-6 – reference: 15597858 - Eur J Gynaecol Oncol. 2004;25(6):745-8 – reference: 26030369 - Lab Invest. 2015 Aug;95(8):962-72 – reference: 24707459 - Gynecol Oncol Case Rep. 2014 Mar 12;8:24-6 – reference: 17624099 - Eur J Gynaecol Oncol. 2007;28(3):241-4 – reference: 1378991 - Acta Pathol Jpn. 1992 May;42(5):372-5 – reference: 9784334 - Gynecol Oncol. 1998 Oct;71(1):133-6 – reference: 22268990 - Diagn Pathol. 2012 Jan 23;7:9 – reference: 12819394 - Int J Gynecol Pathol. 2003 Jul;22(3):266-71 – reference: 25366470 - J Ovarian Res. 2014 Nov 04;7:91 – reference: 29217359 - J Chin Med Assoc. 2018 Feb;81(2):155-163 |
| SSID | ssj0062843 |
| Score | 2.199099 |
| SecondaryResourceType | review_article |
| Snippet | Background
Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis... Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis and further... Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis... BackgroundAlpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both diagnosis... Abstract Background Alpha-fetoprotein (AFP) is a useful tumor marker for ovarian germ cell tumors, particularly yolk sac tumor (YST). It is valuable for both... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 52 |
| SubjectTerms | Adenocarcinoma Alpha fetoproteins Alpha-fetoprotein Antigens Case Report Case reports CD30 antigen Cell differentiation Chemotherapy Cytokeratin Diagnosis Fetal gut differentiation Fetus Fetuses Gynecology Health aspects Heparan sulfate proteoglycans Immunoreactivity Literature reviews Medicine Medicine & Public Health Metastasis Microbiota (Symbiotic organisms) Obstetrics Ovarian cancer Ovarian carcinoma Ovarian clear cell adenocarcinoma Patients Post-menopause Postmenopausal women Reproductive Medicine Stains & staining Surgery Tomography Tumor cells Tumor markers Tumors Vagina Yolk Yolk sac α-Fetoprotein |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0EI99YKA8lhaipEQSCCriR0_wm1BVBUSnKjUm2U7DlRqk6rNIvEDfDczdhKaIuDCIZf1OPHOjOdhz4OQ5zHIGvSMYrpwnlXSNazm0jAhtYiFK42JeKP78ZM6Oq4-nMiTa62-MCYslwfOiDsAi7kGHelBc4mqLqWJhXRlYxSGxImY8siLupicqSyDFQhdMd5hlkYdXIGkrjBoCx5QScwstFAq1v-7SL6mk27GS964NE266PAOuT0akXSdF3-X3IrdPbKz7sCBPv9OX9AU1pnOy3fIjzVm07I2Dn2qyXDasYtU5RXeTPtv4Cq7jgZsHkHxEJ86EESg3y5hvD93FM9pKUyGz33ZDHTqpzJkir6hjoK3HWkAZUjz_QN1XUPP5mrNNCfH3CfHh-8_vztiY_MFFpSoBuZlBL0F9lRQQTqQgk4HaZpaBe9L7HalRWt80B7oK40GS4obL7wTrYgygNn4gGx1fRcfESobXbe-4TDiq4Z7F4VuPfhCxksVVLMixUQMG8bK5Ngg48wmD8Uom-lngX4W6WfNiryap1zkshx_A36LFJ4BsaJ2-gH4zI58Zv_FZyvyFPnD5vTUWS7YtcQDBs5NuSIvEwRKBlh-cGOCAyABa2wtIPcWkLCjw3J44kE7SpQry8EWNGD-VdWKPJuHcSZGyXWx3yAMOH-FrhWs9mFm2flPg9khhJbwcr1g5gVWliPd6ddUb1yhna1g5uuJ7X8t649If_w_kL5LtnnatIpxvke2hstNfAJG4OD3037_CfaqVeI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKuXBBQHmEFjASAglkuonjR5AQWhBVhVROrNSbZTtOqbRNyjZb0T_A72bGeUBK6WEv8TjreF7f-DFDyIvgRQF-RjI1s47lwpasyIRmXCgeZjbVOuCO7sFXub_IvxyKww0ylLfqJ_DsytAO60ktVsu3P39cfACFfx8VXsvdM7DDOR7Jgh84HKZvkJvgmCTGYgf5uKkgwRLzfmPzym4T1xQz-P9rp_9yVJcPUV7aSY0Oau8Oud0jSzrvROEu2Qj1PbI1ryGqPrmgL2k86xkX0bfIrzlesWVVaJuYqOG4Zqcx9Su8mTbnED_bmnqsKEFxZZ9asE7g9FbQ3pxYiou3FDrD3x2tWzoUWWk7Nr-jlkIIHqgHD0m7TQlq65IuxxTOtLsxc58s9j5_-7TP-ooMzEuet8yJAM4MQJaXXlgwjVZ5octCeudSLIGleKWdVw6YLrQCeJVpx53lFQ_CA5Z8QDbrpg6PCBWlKipXZtDi8jJzNnBVOQiQtBPSyzIhs4EZxvfpyrFqxtLEsEVL0_HPAP8M8s_ohLweu5x2uTquI_6IHB4JMc12fNCsjkyvtQbCtQIAmgPYxPMiFTrMhE1LLfE8Jg8qIc9QPkx3Z3U0FmYucNUhy3SakFeRAgUYhu9tf-sBJgETb00odyaUoOZ-2jzIoBm0xGQAEDVgwjxPyPOxGXvi0bk6NGukgYhwpgoJo33Yiez40YBFOFcCXq4mwjyZlWlLffw9JiGXCL4l9HwziP2fYf130h9f_xHb5FYW1VGyLNshm-1qHZ4A5mvd06jJvwFy2FK9 priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1baxUxEA5aQXwRbb2sVo0gCkpwN9lc1rdjsRShPlnoW0iyWS20u6XdI_QP9Hc7k73YrRfwYV9OJrs5mcnMN5lkhpBXMcgK7IxiOneeldLVrOLSMCG1iLkrjIkY0d3_ovYOys-H8nBMFo13Ya7G7wuj3p-Dji3xuBU8YEyYuUluyQK0LsZl1c6kdBVoWTEGLf_YbWF2Unb-33XwFSN0_YDktShpMj6798jdETXS1cDm--RGbDfJ1qoFj_nkgr6m6Rxn2iDfJLf3x3D5Frlc4U1a1sS-S_kYjlp2mjK8wkdo9wPcZNfSgIUjKG7gUwdKCGzbGbR3J47iHi2FzvDlb-ueTrVU-oGbH6ij4GlHGsAQ0iH2QF1b0-M5UzMdLsY8IAe7n77u7LGx8AILSpQ98zKCzQIsFVSQDjSg00GaulLB-wIrXWnRGB-0B95KowFFceOFd6IRUQaAjA_JRtu18TGhstZV42sOLb6suXdR6MaDH2S8VEHVGcknvtgwZiXH4hjHNnknRtmBlRZYaZGV1mTk7dzldEjJ8S_ij8jsmRCzaacfQMjsuDgteGUV4DAP6EiUVSFNzKUraqPw2KWIOiMvUFTscDV11gl2JXFzgXNTZORNokCtAMMPbrzcAJOA-bUWlNsLSljNYdk8iaMdtcm55YADDUC_sszIy7kZe-IJuTZ2a6QBxy_XlYLRPhqkd_7TADmE0BJerhdyvZiVZUt79D3lGleIsRX0fDetgF_D-uukP_kv6qfkDk8LVTHOt8lGf7aOzwDp9f55WuM_AfWmS3I priority: 102 providerName: Springer Nature |
| Title | Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review |
| URI | https://link.springer.com/article/10.1186/s13048-018-0426-8 https://www.ncbi.nlm.nih.gov/pubmed/29933751 https://www.proquest.com/docview/2071874144 https://www.proquest.com/docview/2058507967 https://pubmed.ncbi.nlm.nih.gov/PMC6015461 https://doaj.org/article/1749846b819349158e05a1d8609433e7 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxQxFA5t98UXUetlta4RREEZ3JlMLiOITJeWstBF1ELfQpLJ1kI7s25nBf-Av9tzMpc6Ffuw-zBJ5pJz8p1LTs4h5JV3PAM5IyI5NTZKuSmiLOEqYlwyPzWxUh53dI8X4ugknZ_y0y2y6M7CYFhlh4kBqIvKoY8cPSFYPg70_0-rHxFWjcLd1a6EhmlLKxQfQ4qxbTICSFbA96P9g8XnLx02CwBj1u5txkq8vwIETzGYC34gqiI1kE4hif-_UP2XrLoZR3ljMzXIqMN75G6rXNK84Yb7ZMuXD8huXoJhffmLvqYh3DP40XfJ7xxP2UZLX1chV8N5Ga1C9le4M61-ggltSuqwqARF5z41AFAg99bQXl0aiv5bCoPhcWebmnZ1VuqG0h-ooWCFe-pASNJmX4KasqAXfRZn2hyaeUhODg--zY6itihD5ARL68hyD_IMJtkJxw2go5GOqyITztoYq2BJtlTWSQt050qChpUoy6xhS-a5A3XyEdkpq9I_IZQXMlvaIoEWmxaJNZ7JpQUbSVkunCjGZNoRQ7s2YzkWzrjQwXJRQjf000A_jfTTakze9kNWTbqO2zrvI4X7jphpO1yo1me6XbgaLLYMdDQLmhNLs5grP-UmLpTAkEzm5Zi8QP7QzbHVHi90ztHxkCQqHpM3oQciBry-M-3BB5gEzL016Lk36Akr3Q2bOx7ULdJc6et1MSYv-2YcidFzpa822AeMwqnMBLzt44Zl-48GdYQxyeHmcsDMg1kZtpTn30MecoH6t4CR7zq2v36t_07609s_4hm5k4TlKKIk2SM79Xrjn4PaV9sJ2ZanckJGeT7_Op-0KxuuzsRsElwp8H-cqj9gzFts |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQw0Kq2D_CCgHIsFGokDglksYljx0Gq0BZatbRdIdRKfTO24y2V2mTZA9Qf4LP4Nmaco6SIvvVhX-Jx1s6M5_BchDz3TmQgZyRLB8ayRJicZbFQjIuU-4GJlPLo0d0fye3D5NOROFoiv5tcGAyrbHhiYNR56fCOHG9CsH0c6P_vJ98Zdo1C72rTQsPUrRXy9VBirE7s2PXnP8GEm63vfAR8v4jjrc2DD9us7jLAnOTJnFnhgUHDLCedMHDcTeqEyjPprI2wrVPKx8q61MJGhEpBZYiV5dbwMffCZVj4AETAMqgdWdIjyxubo89fGlkggfnz2pcaKfl2BhIjweAx-IFoZKojDUPTgH9Fw1-y8XLc5iXnbZCJW7fJrVqZpcOK-u6QJV_cJSvDAgz5s3P6kobw0nBvv0J-DTGrl439vAy1IU4KNgnVZuHNtPwBJrspqMMmFhSdCdQAQwQ5O4Xx8sxQvC-mMBn-7ngxp01fl3lFWe-ooWD1e-pAKNPKD0JNkdPTtmo0rZJ07pHDa0HPfdIrysI_JFTkaTa2eQwjNsljazxPxxZsMmWFdDLvk0GDDO3qCunYqONUB0tJSV3hTwP-NOJPqz553U6ZVOVBrgLeQAy3gFjZOzwop8e6ZhQaLMQMdEILmhpPskgoPxAmypXEEFDu0z5ZQ_rQVZpsy5_0UOBFRxyrqE9eBQjkULB8Z-pEC_gIWOurA7nagQTO4rrDDQ3qmrPN9MU57JNn7TDOxGi9wpcLhAEjdJBmElb7oCLZdtOg_nCeCnh52iHmzlfpjhQn30Ldc4n6voSZbxqyv1jWfz_6o6s3sUZubB_s7-m9ndHuY3IzDkdTsjheJb35dOGfgMo5t0_rc03J1-tmJX8ADZqTXw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgK1VcELRAty3USAgkkNUkjh_hFh6rstAKCSr1ZtmOUyq1yWo3i8Qf4Hczdh6Q8pA45LIeJ16PZ-Ybjz2D0BNnWQZ2hhMRaUNSpguSJUwSygR1kY6ldD6ie3zCj07T-Rk76-qcrvrT7n1Isr3T4LM0Vc3hoihbEZf8cAWaN_WHsOABE0PkTbQhPRSfoI08n3-a98qYg_alXTDzjx1H5ihk7f9dN_9inK4fnLwWPQ1GaXYH3e7QJM5b9t9FN1y1hbbzCjzpq2_4KQ7nO8PG-RbaPO7C6Nvoe-5v2JLSNXXI03BRkUXI_AofwfVXcJ91ha0vKIH9xj7WoJzA5i2hvb7S2O_dYugMXz5fN7ivsdK0XH6JNQYP3GELBhK3MQmsqwJfDhmccXth5h46nb39_PqIdAUZiOU0bYhhDmwZYCzLLdOgGbWwTBYZt8bEvgKWoKU0VhjgOZMC0FUiDTWaltQxC1DyPppUdeV2EGaFyEpTJNBi0iIx2lFRGvCPpGHc8mKKop4vynbZyn3RjEsVvBbJVctKBaxUnpVKTtHzocuiTdXxL-JXntkDoc-yHX6ol-eqE1oF3loG-MwAaqJpFjPpIqbjAlZallLqxBQd-KWi2iurg65QOfObDkki4yl6Fii8toDhW91deoBJ8Hm3RpT7I0qQcjtu7pej6rTMSiWADyVAwjSdosdDs-_pT85Vrl57GnAII5FxGO2DdvUOfxqgCKWCwcvFaF2PZmXcUl18CTnIucfeHHq-6CXg57D-Oum7_0V9gDY_vpmpD-9O3u-hW0mQWU6SZB9NmuXaPQQw2JhHncD_AHHSWBE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alpha-fetoprotein-producing+ovarian+clear+cell+adenocarcinoma+with+fetal+gut+differentiation%3A+a+rare+case+report+and+literature+review&rft.jtitle=Journal+of+ovarian+research&rft.au=Wei-Ting%2C+Chao&rft.au=Chia-Hao%2C+Liu&rft.au=Lai%2C+Chiung-Ru&rft.au=Chen%2C+Yi-Jen&rft.date=2018-06-22&rft.pub=BioMed+Central&rft.eissn=1757-2215&rft.volume=11&rft_id=info:doi/10.1186%2Fs13048-018-0426-8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-2215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-2215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-2215&client=summon |